Nephrectomy Overview

What "nephrectomy" means

Nephrectomy means surgical removal of a kidney. The word covers several different operations, and the right one depends on the diagnosis:

• Simple nephrectomy removes an entire kidney for selected non-cancer indications, such as a kidney that no longer works and is causing ongoing problems.
• Radical nephrectomy is the whole-kidney operation used for kidney cancer; its exact extent is based on the anatomy of the tumour, not a fixed template.
• Partial nephrectomy removes the tumour while preserving the uninvolved part of the kidney. It is also called nephron-sparing or kidney-sparing surgery, because the aim is to remove the tumour while preserving as much functioning kidney tissue as possible.

These are three different operations for three different situations, and none of them is automatically "better" in isolation — the choice depends on the diagnosis, the tumour, and the person.

Radical nephrectomy generally removes the whole kidney together with the surrounding perinephric tissue required for oncologically appropriate excision; the adrenal gland and lymph nodes are not automatically removed and are dealt with separately according to clinical findings. It is therefore important not to assume that a radical nephrectomy automatically means the kidney, the adrenal gland and all surrounding lymph nodes are removed together. Adrenalectomy and lymph-node dissection are not automatic; they depend on findings, discussed further below.

Service scope on this website

Open nephrectomy, laparoscopic nephrectomy, simple nephrectomy where indicated, and radical nephrectomy where indicated are offered as personal services. Partial nephrectomy and robotic approaches (including robotic nephrectomy and robotic partial nephrectomy) are included here for patient education and treatment comparison; they are not listed as personally offered services on this website. Where a case may be better suited to partial nephrectomy or a robotic approach, appropriate urological or uro-oncology referral is discussed rather than treating the offered procedures as a universal substitute.

Which guidance this page follows

The cancer-related sections of this page follow the European Association of Urology (EAU) Guidelines on Renal Cell Carcinoma, 2026 edition. The EAU records that the 2026 RCC Guidelines are a limited update of the 2025 publication. Recommendation strengths quoted below ("strong" or "weak") are the EAU's own wording. Non-cancer reasons for removing a kidney are not covered by that cancer guideline and are described here in general terms only.

Small kidney cancers: is the whole kidney always removed?

In simplified terms, T1 tumours are confined to the kidney and are up to 7 cm in size, while T2 tumours are larger than 7 cm but are still confined to the kidney; T1a refers to tumours up to 4 cm. Full staging depends on more than size alone and is confirmed through appropriate imaging and pathology.

No. For localized kidney (renal cell) cancer, current EAU guidance is to offer surgery aimed at cure, but this does not mean whole-kidney removal is the automatic first choice. For T1 tumours — the smaller, more localized cancers — partial nephrectomy is the recommended approach when feasible (a strong recommendation). Partial nephrectomy may also be offered to selected T2 tumours in people with a solitary kidney or chronic kidney disease when technically feasible, though this is a weaker recommendation reflecting less certain evidence.

Because partial nephrectomy is included on this website for education rather than as a personally offered service, patients whose tumour looks technically suitable for kidney-sparing surgery may need referral to an appropriate urological or uro-oncology service for that option to be properly considered. A feasible partial nephrectomy elsewhere should not be replaced by an offered radical nephrectomy simply because radical nephrectomy is within this practice's scope; that distinction between what is offered here and what represents the appropriate standard of care for a given tumour is important and is discussed openly with each patient.

When radical (whole-kidney) nephrectomy is appropriate

Radical nephrectomy remains an appropriate, guideline-supported operation for T2 tumours and for localized masses that are not suitable for partial nephrectomy. Current EAU guidance recognizes laparoscopic or robotic radical nephrectomy in suitable T2 or non-partial-nephrectomy-suitable cases (a strong recommendation), performed as an open, laparoscopic or robotic procedure depending on anatomy and circumstances. On this website, open and laparoscopic nephrectomy are the offered services; robotic nephrectomy is described here for education and referral only.

Two related points matter. First, minimally invasive radical nephrectomy should not be performed for T1 tumours where partial nephrectomy is feasible by any approach, including open surgery — removing the whole kidney is not an acceptable substitute for an achievable kidney-sparing operation simply because it can be done with smaller incisions (a strong recommendation). Second, a minimally invasive approach should not be used where it might compromise cancer clearance, kidney function or perioperative safety (also a strong recommendation).

Open, laparoscopic and robotic: what the approach means

Open, laparoscopic and robotic surgery are different surgical approaches, not different levels of "how advanced the cancer treatment is." The correct approach for a given patient depends on tumour anatomy, whether kidney preservation is feasible, involvement of major blood vessels, previous surgery, individual patient factors, surgeon expertise and available resources.

Current evidence indicates that laparoscopic radical nephrectomy has lower morbidity than open surgery, and that short-term oncological outcomes for selected T1–T2a disease are comparable between approaches. Robotic radical nephrectomy has not been shown to be universally superior to well-performed laparoscopic surgery. Robotic surgery is not automatically "the most advanced," "the best," "the safest," or associated with "less recurrence" than a well-performed laparoscopic or open operation — the appropriate approach is decided case by case.

The adrenal gland

The adrenal gland sits above the kidney but is a separate organ. Current guidance is not to perform removal of the adrenal gland on the side of surgery when there is no clinical evidence that the adrenal gland is involved (a strong recommendation). In practice, this means the adrenal gland is not routinely removed simply because the kidney is being removed; adrenal removal depends on imaging findings or operative concern for involvement, assessed individually.

Lymph nodes

Similarly, routine lymph-node dissection is not performed for cancer that is confined to the kidney (a weak recommendation reflecting the balance of evidence). It is not accurate to say that radical nephrectomy always includes lymph-node dissection. Clinically enlarged lymph nodes may be removed for staging and prognostic information in more advanced disease, as part of individualized planning.

Not every renal mass needs immediate surgery

Finding a mass on the kidney does not automatically mean immediate nephrectomy is required. Current EAU guidance supports active surveillance for selected patients with small (cT1a), localized tumours where there is no indication for immediate treatment, with delayed intervention if the tumour later changes (a weak recommendation). Tumour ablation or stereotactic ablative radiotherapy (SABR) may be offered to selected patients with cT1 tumours who need treatment but are not fit for surgery (also a weak recommendation); a biopsy of the renal mass is required before ablation is carried out (a strong recommendation).

These pathways are not offered as personal services on this website and are not promoted here as a routine alternative to surgery; they are mentioned so that patients understand the options that exist and can be discussed through an appropriate urology or uro-oncology service, particularly where age, other medical conditions, or the characteristics of the tumour make immediate surgery less attractive.

Removing a kidney for reasons other than cancer

A kidney that no longer works well, or that has been chronically damaged, can sometimes be removed for reasons unrelated to cancer. Examples of situations where this may be considered include a chronically infected or non-functioning kidney, kidney destruction from long-standing obstruction, or severe symptoms arising from a kidney that no longer works. Recurrent infection, stones, obstruction or poor renal function alone do not automatically mean that a kidney should be removed; nephrectomy is considered only when the overall clinical picture justifies removal and the expected function of the remaining kidney has been assessed. This is not a claim that every poorly functioning kidney needs to be removed — the decision depends on individual urological evaluation, including how the rest of the urinary system and the other kidney are functioning.

Getting ready for surgery

Preoperative assessment is individualized, but commonly includes confirming the diagnosis and indication for surgery, assessing overall kidney function and the health of the other kidney, relevant blood tests, appropriate imaging, cancer staging where a cancer is suspected, anaesthetic assessment, a review of your medicines, careful management of any blood-thinning or antiplatelet medicines, and assessment of other medical conditions. Where a case looks more suited to a nephron-sparing (kidney preserving) approach, referral for that option is considered as part of this assessment. Not every patient needs every imaging test, and any change to blood-thinning or antiplatelet medicine should be decided with the clinician managing that medicine, not made independently.

Before an entire kidney is removed, overall kidney function — usually including serum creatinine and estimated glomerular filtration rate (eGFR) — and the expected function of the remaining kidney are assessed. When the contribution of each kidney is clinically important, a renal nuclear-function study may be used to estimate split or differential renal function. This is particularly relevant in selected patients with impaired renal function, a solitary kidney, bilateral or multiple renal tumours, or a poorly functioning kidney being considered for simple nephrectomy. Such a scan is not required for every nephrectomy, and blood tests alone do not by themselves prove that the remaining kidney will be adequate; assessment is individualized.

For a suspected renal tumour, cross-sectional imaging — most commonly multiphasic contrast-enhanced CT, with MRI used in selected situations — is used to characterize the mass and to assess its local extent and staging. Investigation is individualized, and not every patient needs every scan. Where nephrectomy is being considered for a chronically damaged, infected or poorly functioning kidney, urine testing or culture and assessment of differential renal function may be required depending on the underlying cause and the clinical situation, rather than as a routine test for everyone.

Smoking status, weight, diabetes, blood pressure and other cardiovascular or renal risk factors are relevant both to surgical recovery and to long-term kidney health, and are addressed as part of routine perioperative care.

Advanced or complex disease

Some situations require referral to a specialist team and multidisciplinary (MDT) planning rather than management by a single surgeon. These include tumour extending into the major veins (venous tumour thrombus), locally advanced kidney cancer, metastatic (spread) kidney cancer, complex partial nephrectomy, a solitary kidney, significant chronic kidney disease, tumours affecting both kidneys, and inherited kidney-cancer syndromes — situations where preserving kidney function is particularly important.

Current guidance notes that tumour with non-metastatic venous thrombus may require removal of the tumour together with the thrombus, and that locally advanced or unresectable disease requires multidisciplinary planning. A single general or urological surgeon does not independently provide the entire pathway for advanced kidney cancer; these situations are managed through appropriate specialist and multidisciplinary services.

Pathology and the final diagnosis

The removed kidney or tumour specimen is sent for histopathological examination. Where cancer was suspected, final pathology confirms the tumour type and provides pathological features such as grade and stage that help determine subsequent follow-up. Imaging before surgery cannot give histological certainty, and occasionally a renal mass that appeared suspicious for malignancy on imaging proves to be benign on final pathology.

Living with one kidney

Many people live well for the rest of their lives with a single functioning kidney. Future kidney function after nephrectomy depends on several factors, including your kidney function before surgery, the health of the remaining kidney, and conditions such as diabetes and high blood pressure that can affect kidney function over time. Because of this, kidney function is assessed before surgery and monitored afterwards as part of routine follow-up. Having one kidney does not automatically lead to kidney failure, but it is not accurate to promise that kidney function will always remain completely normal either — outcomes vary between individuals.

Follow-up after nephrectomy may include serum creatinine and eGFR, blood-pressure assessment and, where clinically appropriate, urine-protein assessment. Patients with pre-existing chronic kidney disease, limited renal reserve or significant risk factors for future renal deterioration may benefit from nephrology input; this is not a routine referral for everyone. Dialysis is not expected after a routine one-sided nephrectomy when the remaining kidney has adequate function, but the risk is different in people with substantially reduced baseline renal reserve — one of the reasons kidney function is assessed before surgery.

Follow-up after surgery for kidney cancer

After surgery for renal cancer, oncological follow-up is individualized according to the final pathology and the estimated risk of recurrence. Depending on that risk, follow-up may include scheduled chest and abdominal imaging together with ongoing assessment of kidney function and general health. No fixed imaging timetable is set out in this general guide, and comprehensive oncology follow-up is not presented as a service personally provided here; it is arranged through the appropriate urology or uro-oncology service.

Recovery

Recovery after nephrectomy varies and depends on whether the operation is open or laparoscopic, the underlying indication, how complex the tumour or kidney anatomy is, your occupation, whether any complications occur, and your general health. Because of this variation, no fixed discharge day, fixed time off work, or guaranteed faster recovery with one approach over another can be promised in general terms; recovery expectations are discussed individually before and after surgery.

Pain and discomfort are expected after nephrectomy and are managed according to the operation and the individual patient; pain severity and duration vary between people, and no approach is painless.

Most people with one healthy functioning kidney do not need a special "kidney diet" solely because one kidney has been removed. General healthy eating, avoiding excessive salt, maintaining an appropriate weight, and following individualized advice if chronic kidney disease is present matter more than rigid restrictions. Excessive water intake is not required; hydration advice depends on the individual clinical situation.

Risks

As with any major operation, nephrectomy carries risks that are discussed individually before surgery, including bleeding that may require transfusion, infection, injury to nearby structures such as bowel, spleen, pancreas, liver or the diaphragm and lung cavity, injury to blood vessels, deep-vein thrombosis or pulmonary embolism, chest infection or other respiratory complication, anaesthetic or other medical complications, reduction in overall kidney function, acute kidney injury, longer-term risk of chronic kidney disease, the possibility of conversion from a laparoscopic to an open operation if needed for safety, wound or port-site complications, and incisional or port-site hernia — with some patients, depending on the approach, developing persistent numbness, weakness or bulging of the flank or abdominal wall. Where cancer is the reason for surgery, the risk of recurrence or progression afterwards depends on the specific pathology and stage found, which is discussed once results are available.

Common myths

Myth: Every kidney tumour needs the whole kidney removed. Fact: For localized T1 tumours, kidney-sparing partial nephrectomy is the recommended approach where feasible. Whole-kidney removal is not automatically the preferred operation for a small, localized cancer.

Myth: Radical nephrectomy always includes removal of the adrenal gland. Fact: Current guidance recommends against removing the adrenal gland when there is no clinical evidence of adrenal involvement. Adrenal removal depends on imaging or operative findings, not routine practice.

Myth: Radical nephrectomy always includes lymph-node dissection. Fact: Routine lymph-node dissection is not recommended for cancer confined to the kidney. Enlarged nodes may be removed for staging in more advanced disease, but this is not automatic.

Myth: Robotic nephrectomy is always superior to other approaches. Fact: Robotic radical nephrectomy has not been shown to be universally superior to well-performed laparoscopic surgery. The right approach depends on the individual case, not on which technology is used.

Myth: Living with one kidney inevitably leads to kidney failure. Fact: Many people live well with a single functioning kidney for the rest of their lives. Future kidney function depends on baseline kidney health, the remaining kidney, and conditions such as diabetes and high blood pressure, and is monitored rather than assumed to fail.

Myth: A small renal mass always needs immediate surgery. Fact: In selected patients with small, localized (cT1a) tumours, active surveillance may be appropriate, and ablative treatments may be considered for selected patients unfit for surgery. Not every small mass requires immediate nephrectomy.